Quantifying the Resolution of Spatial and Temporal Representation in Children with 22Q11.2 Deletion Syndrome Kathryn L
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(Lcrs) in 22Q11 Mediate Deletions, Duplications, Translocations, and Genomic Instability: an Update and Literature Review Tamim H
review January/February 2001 ⅐ Vol. 3 ⅐ No. 1 Evolutionarily conserved low copy repeats (LCRs) in 22q11 mediate deletions, duplications, translocations, and genomic instability: An update and literature review Tamim H. Shaikh, PhD1, Hiroki Kurahashi, MD, PhD1, and Beverly S. Emanuel, PhD1,2 Several constitutional rearrangements, including deletions, duplications, and translocations, are associated with 22q11.2. These rearrangements give rise to a variety of genomic disorders, including DiGeorge, velocardiofacial, and conotruncal anomaly face syndromes (DGS/VCFS/CAFS), cat eye syndrome (CES), and the supernumerary der(22)t(11;22) syndrome associated with the recurrent t(11;22). Chromosome 22-specific duplications or low copy repeats (LCRs) have been directly implicated in the chromosomal rearrangements associated with 22q11.2. Extensive sequence analysis of the different copies of 22q11 LCRs suggests a complex organization. Examination of their evolutionary origin suggests that the duplications in 22q11.2 may predate the divergence of New World monkeys 40 million years ago. Based on the current data, a number of models are proposed to explain the LCR-mediated constitutional rearrangements of 22q11.2. Genetics in Medicine, 2001:3(1):6–13. Key Words: duplication, evolution, 22q11, deletion and translocation Although chromosome 22 represents only 2% of the haploid The 22q11.2 deletion syndrome, which includes DGS/ human genome,1 recurrent, clinically significant, acquired, VCFS/CAFS, is the most common microdeletion syndrome. and somatic -
Williams Syndrome Specialized Health Needs Interagency Collaboration
SHNIC Factsheet: Williams Syndrome Specialized Health Needs Interagency Collaboration What is it? Williams syndrome (WS) is a random genetic mutation disorder that presents at birth, affecting both boys and girls equally. WS is caused by the deletion of genetic material from a specific region of chromosome 7. This disease is characterized by an array of medical problems that can range in severity and age of onset. However, all cases are characterized by dysmorphic facial features, cardiovascular disease, and developmental delay. These disabilities occur in conjunction with striking verbal abilities, highly social personalities, and an affinity for music. What are characteristics? Heart and blood vessel problems Low muscle tone and joint laxity Reflux Dental abnormalities Hypercalcemia Developmental Delays Hearing sensitivity Characteristic facial features: Kidney problems small upturned nose Hernias wide mouth Facial characteristics full lips Chronic ear infection small chin puffiness around the eyes Suggested school accommodations Most children with Williams Syndrome have some form of learning difficulties but they can significant- ly vary. As they age, you may notice the child struggling with concepts like spatial relations, numbers and abstract reasoning. Many children with WS appear scattered in their level of abilities across do- mains. Although a child with WS may be very social, remember to monitor their support systems and social interactions as they often have a difficult time understanding social cues. Physical/Medical -
The Symptom Profile and Experience of Children with Rare Life-Limiting Conditions
The symptom profile and experience of children with rare life-limiting conditions: Perspectives of their families and key health professionals Document Title The symptom profile and experience of children with rare life-limiting conditions: Perspectives of their families and key health professionals Authors Cari Malcolm, Sally Adams, Gillian Anderson, Faith Gibson, Richard Hain, Anthea Morley, Liz Forbat. Publisher Cancer Care Research Centre, University of Stirling Publication Date 2011 Target Audience Paediatric palliative care staff, paediatric clinicians, policy-makers, service developers, families supporting children with life-limiting conditions. Funded By Children’s Hospice Association Scotland Key Words Advance care planning, Batten disease, expertise, extended family, family, Morquio disease, progressive life-limiting, relationships, Sanfilippo disease, siblings, symptoms. Contact Details www.cancercare.stir.ac.uk Tel: 01786 849260 Email: [email protected] Copyright This publication is copyright CCRC and may be reproduced free of charge in any format or medium. Any material used must be fully acknowledged, and the title of the publication, authors and date of publication specified. The symptom profile and experience of children with rare life- limiting conditions: Perspectives of their families and key health professionals Executive Summary Background Many non-malignant life-limiting conditions are individually extremely rare and little is known, even by professionals in the field, about the actual day-to-day symptomatology or the impact of these symptoms on the child and family. With little recorded in the literature regarding the symptoms that children with rare life-limiting conditions experience, and the associated impact of managing these symptoms on the wider family, an opportunity exists to widen the knowledge base in this area. -
Chromosome 22Q11.2 Deletion Syndrome (Digeorge and Velocardiofacial Syndromes) Elena Perez, MD, Phd, and Kathleen E
Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes) Elena Perez, MD, PhD, and Kathleen E. Sullivan, MD, PhD Chromosome 22q11.2 deletion syndrome occurs in Overview approximately 1 of 3000 children. Clinicians have defined the Chromosome 22q11.2 deletion syndrome is the name phenotypic features associated with the syndrome and the given to a heterogeneous group of disorders that share a past 5 years have seen significant progress in determining the common genetic basis. Most patients with DiGeorge frequency of the deletion in specific populations. As a result, syndrome and velocardiofacial syndrome have monoso- caregivers now have a better appreciation of which patients mic deletions of chromosome 22q11.2 [1,2]. Other syn- are at risk for having the deletion. Once identified, patients dromes in which a substantial fraction of patients have with the deletion can receive appropriate multidisciplinary care. been determined to have the deletion are conotruncal We describe recent advances in understanding the genetic anomaly face syndrome,Caylor cardiofacial syndrome, basis for the syndrome, the clinical manifestations of the and autosomal dominant Opitz-G/BBB syndrome. Com- syndrome, and new information on autoimmune diseases in plicating the situation further is the fact that not all pa- this syndrome. Curr Opin Pediatr 2002, 14:678–683 © 2002 Lippincott tients with hemizygous deletions of chromosome Williams & Wilkins, Inc. 22q11.2 have identical deletions. Despite the heteroge- neity of both the clinical manifestations and the chromo- somal deletions,much progress has been made in the last year in understanding the genetic basis of the chromo- some 22q11.2 deletion syndromes. -
Williams Syndrome (WS): Recent Research on Music and Sound
American Music Therapy Association 8455 Colesville Rd., Ste. 1000 • Silver Spring, Maryland 20910 Tel. (301) 589-3300 • Fax (301) 589-5175 • www.musictherapy.org Williams Syndrome (WS): Recent Research on Music and Sound STATEMENT OF PURPOSE Description: Music Therapy (MT) is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Although WS is a rare disease, MTs may have more contact with these clients since many people with WS have a strong affinity for music, melody and song. Parents of children with WS express a strong interest in adaptive music programs for their children. The aim of therapy is to help people with WS to optimize their talents and musical affinity in order to address multiple potential outcomes. MT sessions may include the use of active music making, singing, interactive music play, and improvisational techniques. MT may include both individual and group therapy. STANDARDIZATION: MT sessions are documented in a treatment plan and delivered in accordance with standards of practice. Music selections and certain active music making activities are modified for client preferences and individualized needs (i.e., song selection, musical instruments, and music may vary). REPLICATION: Yes; MT and music special education has been used with different settings, providers, and populations. Research replication in the area of music response and WS is growing. OUTCOMES: Improved global state, enhanced learning, general functioning, improved social functioning, and enhanced leisure time. OVERVIEW OF RESEARCH The prevalence rate for WS is estimated at 0.01% or about 36,266 people in the United States. -
Digeorge Syndrome in a Newborn - a Diagnostic Challenge
Carvalho V, et al., J Neonatol Clin Pediatr 2020, 7: 061 DOI: 10.24966/NCP-878X/100061 HSOA Journal of Neonatology and Clinical Pediatrics Case Report manifestations in order to allow anearly multidisciplinary orientation, DiGeorge Syndrome in a as well as to provide genetic counseling to the patient’s relatives. Keywords: 22q11 Deletion syndrome; Combined syndromic immu- Newborn - A Diagnostic no deficiencies; DiGeorge syndrome Challenge Introduction Vasco Carvalho1, Raquel Oliveira1, Joana Vilaça1, Miguel Gonçalves Rocha2, Almerinda Pereira1 and Nicole Silva1 DiGeorge Syndrome (DGS) is mainly caused by the microdeletion of chromosome 22 (22q11.2), being characterized by a broad pheno- 1 Neonatal Intensive Care Unit, Department of Pediatrics, Hospital of Braga, typic spectrum [1-10]. Braga, Portugal 2Genetics Service, Hospital of Braga, Braga, Portugal The microdeletion of chromosome 22q11.2 results in maldevel- opment of both the third and fourth pharyngeal pouches and it is the most common interstitial deletion syndrome, affecting approximate- Abstract ly 1 in every 2.000-6.000 live births, with males and females being Introduction: DiGeorge syndrome is mainly caused by microdele- equally affected [3-5,8-13]. tion of chromosome 22 (22q11.2) and is characterized by a broad phenotypic spectrum. Approximately 90 percent of the patients with DGS have hetero- zygous deletions in chromosome 22q11.2 and typically result from de Description of case: A 35-year-old healthy primigravida was novo microdeletions, therefore supporting a high rate of spontaneous hospitalized due to preterm labor at 29 weeks and four days. deletion. It is important to add that about 10% of the cases are famil- Parents were non-consanguineous with unremarkable family history. -
Preimplantation Genetic Screening and Diagnosis
Lab Management Guidelines v2.0.2019 Preimplantation Genetic Screening and Diagnosis MOL.CU.119.P v2.0.2019 Description Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS) are used to detect genetic conditions, chromosome abnormalities, and fetal sex during assisted reproduction with in vitro fertilization (IVF). PGD refers to embryo testing that is performed when one or both parents have a known genetic abnormality. This includes single-gene mutations and chromosome rearrangements. PGS refers to screening an embryo for aneuploidy when both parents are chromosomally normal. Genetic testing is performed on cells from the developing embryo prior to implantation. Only those embryos not affected with a genetic condition are implanted. PGD may allow at-risk couples to avoid a pregnancy affected with a genetic condition. The Society for Assisted Reproductive Technology and the American Society for Reproductive Medicine have published joint practice committee opinions to address the safety, accuracy, and overall efficacy of PGD and PGS.1,2 This guideline does not include prenatal or preconception carrier screening. Please refer to Genetic Testing for Carrier Status for that purpose. This guideline does not include prenatal genetic testing. Please see Genetic Testing for Prenatal Screening and Diagnostic Testing for genetic testing done during pregnancy. Criteria Criteria: General coverage guidance Preimplantation genetic diagnosis may be considered when ALL of the following conditions are met: Technical and clinical validity: The test must be accurate, sensitive and specific, based on sufficient, quality scientific evidence to support the claims of the test. In the case of PGD, the mutation(s) or translocation(s) to be tested in the embryo should first be well-characterized in the parent(s) AND the embryonic test results must be demonstrated to be highly accurate. -
The Behavioural Phenotype of Angelman Syndrome
The behavioural phenotype of Angelman syndrome. Horsler, K. and Oliver, C. Cerebra Centre for Neurodevelopmental Disorders, School of Psychology, University of Birmingham Please use this reference when citing this work: Horsler, K. and Oliver, C. (2006). The behavioural phenotype of Angelman syndrome. Journal of Intellectual Disability Research , 50 , 33-53. The Cerebra Centre for Neurodevelopmental Disorders, School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT Website: www.cndd.Bham.ac.uk E-mail : [email protected] 1 ABSTRACT Background. The purpose of this review is to examine the notion of a behavioural phenotype for Angelman syndrome and identify methodological and conceptual influences on the accepted presentation. Method. Studies examining the behavioural characteristics associated with Angelman syndrome are reviewed and methodology is described. Results. Potential bias in the description of the phenotype emerges with the use of case and cohort studies with the absence of comparison groups. A trend in the literature from a direct gene effect to a socially mediated effect on laughter is evident. Conclusion. Evidence for a behavioural phenotype of Angelman syndrome has begun to emerge. However, by adopting the concept of a ‘behavioural phenotype’, attention may become biased towards the underlying biological basis of the syndrome, with developmental and environmental factors being overlooked. 2 INTRODUCTION Angelman described three children in 1965 who all presented with intellectual disability -
Statistical Analysis Plan
Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This -
7Q Deletions Proximal Interstitial FTNW
7q deletions proximal interstitial rarechromo.org A 7q deletion A 7q deletion is a chromosome disorder . A chromosome disorder is a change in chromosome number or structure which results in a set of features or symptoms. People with a 7q deletion have lost a small but variable amount of genetic material from one of their 46 chromosomes. Chromosomes and genes Chromosomes are made up of DNA and are the structure in the nucleus of the body’s cells that carry genetic information (known as genes), telling the body how to develop and function. They come in 23 pairs, one from each parent. Twenty-two of the pairs are numbered 1- 22 according to size, from the largest to the smallest. In addition to these 44 chromosomes, each person has another pair of chromosomes, called the sex chromosomes. Girls have two Xs (XX), whereas boys have an X and a Y chromosome (XY). Each chromosome has a short (p) arm (at the top in the diagram on the next page) and a long (q) arm (the bottom part of the chromosome). For healthy development, chromosomes should contain just the right amount of material – not too much and not too little. People with a 7q deletion have one intact chromosome 7, but the other chromosome is missing a piece. This means that there is only one copy instead of the usual two of a number of genes. As chromosome 7 is a medium-sized chromosome, the genes on it represent about 4-6 per cent of the total number of genes in the human genome. -
The Fragile X Syndrome–Autism Comorbidity: What Do We Really Know?
REVIEW ARTICLE published: 16 October 2014 doi: 10.3389/fgene.2014.00355 The fragile X syndrome–autism comorbidity: what do we really know? Leonard Abbeduto 1,2*, Andrea McDuffie 1,2 and Angela John Thurman 1,2 1 MIND Institute, University of California, Davis, Sacramento, CA, USA 2 Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento, CA, USA Edited by: Autism spectrum disorder (ASD) is a common comorbid condition in people with fragile Anne C. Wheeler, Carolina Institute X syndrome (FXS). It has been assumed that ASD symptoms reflect the same underlying for Developmental Disabilities; University of North Carolina at psychological and neurobiological impairments in both FXS and non-syndromic ASD, which Chapel Hill, USA has led to the claim that targeted pharmaceutical treatments that are efficacious for core Reviewed by: symptoms of FXS are likely to be beneficial for non-syndromic ASD as well. In contrast, we Molly Losh, Northwestern present evidence from a variety of sources suggesting that there are important differences University, USA in ASD symptoms, behavioral and psychiatric correlates, and developmental trajectories Dejan Budimirovic, Kennedy Krieger Institute/The Johns Hopkins between individuals with comorbid FXS and ASD and those with non-syndromic ASD. We University, USA also present evidence suggesting that social impairments may not distinguish individuals *Correspondence: with FXS with and without ASD. Finally, we present data that demonstrate that the Leonard Abbeduto, MIND Institute, neurobiological substrates of the behavioral impairments, including those reflecting core University of California, Davis, 2825 ASD symptoms, are different in FXS and non-syndromic ASD. Together, these data suggest 50th Street, Sacramento, CA 95817, USA that there are clinically important differences between FXS and non-syndromic ASD e-mail: leonard.abbeduto@ucdmc. -
Hypoparathyroidism and Digeorge Syndrome
Endocrinology and Diabetes Clinic Disorders of Calcium 4480 Oak Street, Vancouver, BC V6H 3V4 604-875-2117 1-888-300-3088 x2117 and Phosphorus http://endodiab.bcchildrens.ca Hypoparathyroidism the parathyroid cells. The body has developed cells that destroy some of its Hypoparathyroidism occurs when the body own tissue. This may include other does not produce enough parathyroid organs and endocrine glands, causing hormone (PTH). This hormone is made in 4 type 1 diabetes, Addison disease or or 5 parathyroid glands, located behind the other autoimmune diseases. thyroid tissue in the neck area. They are 2. Surgery or radiation to the thyroid gland very small—the size of peas. Their only job which damages the parathyroid glands. is to produce PTH, which keeps the calcium levels in the blood in the right range. 3. Iron deposits in the parathyroid glands, a side-effect of repeated transfusions to The name “hypo-parathyroid-ism”, means a treat thalassemia or other blood condition of low parathyroid hormone. diseases What does PTH do? How is hypoparathyroidism diagnosed? PTH balances the calcium level in the blood, keeping it in the right range. When the Something will have happened to make your calcium level is low, PTH is produced and it doctor request special blood tests. Perhaps raises the calcium level by: a heart problem is discovered during a routine pregnancy ultrasound or at birth, or 1. Moving calcium from the bones into the perhaps your baby or child became very sick blood. with symptoms of low blood calcium (see 2. Decreasing how much calcium is handout Disorders of Calcium and eliminated from the blood into the urine Phosphorus).